Contribution of serum level of CCL28 in the diagnosis and evaluation of
Through the detection of changes in serum CCL28 content in Sjögren’s
syndrome (SS), we explored the significance of CCL28 in disease
diagnosis and evaluation. Serum samples were collected from patients
with SS, rheumatoid arthritis (RA), and systemic lupus erythematosus
(SLE). Serum levels of CCL28 were measured using enzyme-linked
immunosorbent assay and compared to healthy controls (HC). We also
detected serum IgA levels and the focus score of labial salivary gland
(LSG) in patients with SS, and explored the correlation with serum
CCL28. In addition, patients with SS were divided into two groups based
on clinical symptoms and laboratory tests. The level of serum CCL28 was
then compared. Serum levels of CCL28 in both primary and secondary SS
patients were significantly lower than those in the HC group, whereas,
serum levels of CCL28 in patients with RA and SLE were not significantly
different from those in the HC group. Comparing with RA and SLE patients
alone, serum levels of CCL28 were dramatically lower in patients with SS
secondary to RA or SLE. No remarkable correlation between serum IgA and
CCL28 levels was observed, while focus score of LSG negatively
correlated with serum CCL28 levels. Serum levels of CCL28 were lower in
patients with SS who suffered from dental carries and thrombocytopenia.
Low serum levels of CCL28 should be considered in the diagnosis of SS.
Serum CCL28 levels reflect the degree of salivary gland injury. In
summary, we concluded that serum CCL28 levels are invaluable in the
diagnosis and evaluation of SS.